This finding is not surprising, because hepatitis C virus infection is associated not only with an increased risk of liver-related events, but also with a greater risk of cardiovascular and renal events [36,37], and support the indication for early treatment of HCV infection among patient with low CD4 T-cell counts, which is now more feasible thanks to the availability of highly-effective, all-oral, short-course regimens.[38]. This evidence concerns the gene CD4 and hepatitis C virus infection.